Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $9.20.

Several analysts recently weighed in on PYXS shares. Royal Bank of Canada restated an "outperform" rating and set a $8.00 price target (down previously from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Stephens started coverage on Pyxis Oncology in a report on Friday, November 8th. They set an "overweight" rating and a $13.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $5.00 price target (down previously from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Finally, William Blair downgraded Pyxis Oncology from an "outperform" rating to a "market perform" rating in a research report on Thursday, November 21st.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds have recently bought and sold shares of PYXS. ProShare Advisors LLC bought a new position in shares of Pyxis Oncology during the 4th quarter worth $26,000. Caption Management LLC bought a new position in shares of Pyxis Oncology during the 4th quarter worth $35,000. Ameriprise Financial Inc. bought a new position in shares of Pyxis Oncology during the 4th quarter worth $35,000. Commonwealth Equity Services LLC grew its position in shares of Pyxis Oncology by 61.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after buying an additional 10,000 shares in the last quarter. Finally, Graham Capital Management L.P. bought a new position in shares of Pyxis Oncology during the 4th quarter worth $47,000. Institutional investors own 39.09% of the company's stock.

Remove Ads

Pyxis Oncology Stock Performance

Shares of PYXS traded up $0.06 during mid-day trading on Wednesday, hitting $1.19. 479,585 shares of the stock were exchanged, compared to its average volume of 762,500. The company has a market cap of $70.76 million, a PE ratio of -1.16 and a beta of 1.06. Pyxis Oncology has a 52-week low of $1.11 and a 52-week high of $6.79. The firm has a 50-day moving average of $1.48 and a two-hundred day moving average of $2.62.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.